Avalo Therapeutics (AVTX) Cash from Financing Activities (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Cash from Financing Activities came in at $1.4 million in Q1 2026, up 103.64% on a QoQ basis from $687000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Cash from Financing Activities data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (down 76.22% YoY) and the FY2025 annual result came in at $14.6 million, down 91.7% from the prior year.
- Cash from Financing Activities advanced to $1.4 million in Q1 2026, from $687000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q1 2024 to a low of -$14.8 million in Q2 2022.
- A 5-year average of $15.6 million and a median of $687000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 6770800.0% in 2024, down 178.93% in 2024.
- Tracing AVTX's Cash from Financing Activities over 5 years: stood at $82000.0 in 2022, then sank by 98.78% to $1000.0 in 2023, then jumped by 6770800.0% to $67.7 million in 2024, then slumped by 98.99% to $687000.0 in 2025, then jumped by 103.64% to $1.4 million in 2026.
- The last three Cash from Financing Activities figures came in at $1.4 million (Q1 2026), $687000.0 (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 410.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 410.21 Mn |
| Jun 30, 2026 | 410.21 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | 687,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Sep 30, 2025 | 14.37 Mn |
| Sep 30, 2025 | 14.37 Mn |
| Jun 30, 2025 | -469,000.00 |
| Jun 30, 2025 | -469,000.00 |
| Dec 31, 2024 | 67.71 Mn |
| Dec 31, 2024 | 67.71 Mn |
| Jun 30, 2024 | -472,000.00 |
| Jun 30, 2024 | -472,000.00 |
| Mar 31, 2024 | 108.61 Mn |
| Mar 31, 2024 | 108.61 Mn |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 10.70 Mn |
| Sep 30, 2023 | 10.70 Mn |